>
Switch to:

Orgenesis Non Operating Income

: $-3.27 Mil (TTM As of Mar. 2022)
View and export this data going back to 2010. Start your Free Trial

Non-Recurring Items are the incomes received or expenses incurred by the business that are not from regular operations. Orgenesis's non-recurring items for the three months ended in Mar. 2022 was $-0.63 Mil. Its non-recurring items for the trailing twelve months (TTM) ended in Mar. 2022 was $-3.27 Mil.

As of today (2022-06-27), Orgenesis's share price is $2.52. Orgenesis's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2022 was $-0.89. Therefore, Orgenesis's PE Ratio without NRI ratio for today is At Loss.


Orgenesis Non Operating Income Historical Data

The historical data trend for Orgenesis's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orgenesis Annual Data
Trend Nov12 Nov13 Nov14 Nov15 Nov16 Nov17 Nov18 Dec19 Dec20 Dec21
Non Operating Income
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.87 -0.91 -0.46 -0.05 -2.71

Orgenesis Quarterly Data
May17 Aug17 Nov17 Feb18 May18 Aug18 Nov18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Non Operating Income Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.07 -0.14 -2.17 -0.33 -0.63

Orgenesis Non Operating Income Calculation

Non-Recurring Items are the incomes received or expenses incurred by the business that are not from regular operations. Examples of NRI include gains (losses) from plant shutdown, lease-breaking fees, lawsuit, write-offs, write-downs, restructuring costs or sales of an investment, discontinued operations etc.

NRI can impact a company's reported income drastically.

Non Operating Income for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.27 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GuruFocus lists a PE Ratio without NRI, which is the price/earnings before NRI. We believe it more accurately reflects the valuation of the company.

Orgenesis's PE Ratio without NRI Ratio for today is calculated as

PE Ratio without NRI=Share Price/EPS without NRI
=2.52/-0.89
=At Loss

Orgenesis's Share Price of today is $2.52.
Orgenesis's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.89.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Orgenesis Non Operating Income Related Terms

Thank you for viewing the detailed overview of Orgenesis's Non Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Orgenesis Business Description

Orgenesis logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
Address
20271 Goldenrod Lane, Germantown, MD, USA, 20876
Orgenesis Inc is a part of the healthcare sector. It is a fully-integrated biopharmaceutical company focused on developing trans-differentiation technologies for diabetes and vertically integrating manufacturing that can optimize its abilities to scale-up its technologies for clinical trials and eventual commercialization. The group operates in two segments namely CDMO and POC. The company is also engaged in applying its disciplined execution to emerging technologies of other cell therapy markets in such areas as cell-based cancer immunotherapies and neurodegenerative diseases.
Executives
Sidransky David director JOHNS HOPKINS UNIVERSITY 720 RUTLAND AVENUE BALTIMORE MD 21205
Reithinger Neil officer: CFO, Treasurer and Secretary 14950 N. 83RD PLACE SUITE 1 SCOTTSDALE AZ 85260
Philips Mario director C/O ATMI, INC DANBURY CT 06810
Ferber Sarah officer: Chief Scientific Officer 17B HAHASKALA STREET TEL AVIV L3 67890
Yachin Guy director 7 ORCHARD WAY N POTOMAC MD 20854
Nanda Ashish director 2301, 23RD FLOOR, TIFFANY TOWERS CLUSTER W, JLT, DUBAI, UAE DUBAI C0 4452
Bedoret Denis officer: See Remarks 48, RUE AUGUSTE PICCARD GOSSELIES C9 6041
Universite Libre De Bruxelles other: less than 10% AVENUE F, ROOSEVELT, 50 BRUSSELS C9 1050
Theodorus Ii Sa other: less than 10% ALLEE DE LA RECHERCHE, 12 BRUSSELS C9 1070
Theodorus Sca other: less than 10% ALLEE DE LA RECHERCHE, 12 BRUSSELS C9 1070
Belenger Olivier other: less than 10% DIEWEG, 69 BRUSSELS C9 1070
Shvartz Oded 10 percent owner 130 BIRUINTEI BVD. PANTELIMON, ILFOV S5 0000000
Bultot Hugues director AVENUE DE L??HORIZON 24 WOLUWE SAINT PIERRE C9 1150
Buyse Chris Georges Frans director BAILLET LATOURLEI 119A BRUSSELS C9 2390
Tenne Joseph officer: CFO Treasurer Secretary 6225 NEIL ROAD, SUITE 300 C/O ORMAT TECHNOLOGIES, INC. RENO NV 89511

Orgenesis Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)